GENFIT/$GNFTY
1D1W1MYTD1Y5YMAX
Capital at risk
About GENFIT
GENFIT S A SP/ADR
- Ticker
- $GNFTY
- Sector
- Health
- Primary listing
- OTC
- Employees
- 161
- Headquarters
- Loos, France
- Website
- www.genfit.com
GENFIT Metrics
BasicAdvanced
$531M
-
-$2.29
-
-
Price and volume
Market cap
$531M
52-week high
$10.20
52-week low
$3.00
Average daily volume
3.8K
Financial strength
Current ratio
1.584
Quick ratio
1.553
Long term debt to equity
-2.293
Total debt to equity
-3.694
Interest coverage (TTM)
-5.17%
Profitability
EBITDA (TTM)
-68.065
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-169.63%
Operating margin (TTM)
-103.58%
Effective tax rate (TTM)
0.37%
Revenue per employee (TTM)
$416,330
Management effectiveness
Return on assets (TTM)
-21.05%
Return on equity (TTM)
-5,189.63%
Valuation
Price to revenue (TTM)
6.615
Price to book
-9.77
Price to tangible book (TTM)
-9.36
Price to free cash flow (TTM)
65.466
Free cash flow yield (TTM)
1.53%
Free cash flow per share (TTM)
0.137
Growth
Revenue change (TTM)
33.03%
Earnings per share change (TTM)
151.10%
3-year revenue growth (CAGR)
27.26%
10-year revenue growth (CAGR)
27.12%
3-year earnings per share growth (CAGR)
43.51%
10-year earnings per share growth (CAGR)
9.22%
What the Analysts think about GENFIT
Analyst ratings (Buy, Hold, Sell) for GENFIT stock.
Analyst projections of the future price of GENFIT stock.
Bulls say / Bears say
Iqirvo is giving GENFIT a growing commercial revenue base through Ipsen: 2025 sales reached US$208 million and triggered a US$20 million milestone, while Ipsen reported €78.8 million of first-quarter 2026 sales. (GENFIT)
The balance sheet gives GENFIT time to develop its pipeline without an immediate equity raise. Cash was €136.1 million at 31 March 2026, and management expects funding to extend beyond the end of 2028, helped by royalty financing. (GENFIT)
The acquisition of nangibotide adds a Phase 2-ready ACLF programme rather than another discovery-stage project. More than 400 people have been exposed in earlier trials, with a favourable reported safety profile and efficacy signals that support a planned Phase 2a study in the fourth quarter of 2026. (GENFIT)
Nangibotide has not yet shown that it works in ACLF. Its supporting efficacy evidence comes from post-hoc analyses in septic shock and COVID-19, while the ACLF proof-of-concept readout is not expected until 2027. (GENFIT)
The stated cash runway is conditional, not guaranteed. GENFIT’s forecast assumes significant future Ipsen milestones and a further optional royalty-financing draw, and excludes exceptional events. (GENFIT)
The MASH diagnostics opportunity is still commercially unproven. Medicare reimbursement currently applies to Labcorp’s test for patients meeting coverage criteria, while wider payer coverage, an IVD launch and physician adoption remain future possibilities exposed to competition and regulatory risk. (GENFIT, BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.
GENFIT Financial Performance
Revenues and expenses
GENFIT Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.